Addex Shares Are Trading Lower After the Company Announced the Phase 2 ADX71149 Epilepsy Study Did Not Achieve Statistical Significance for the Primary Endpoint of Time for Patients to Reach Baseline Seizure Count When ADX71149 Was Added to Standard of Care
Addex 宣布第 2 阶段 ADX71149 癫痫研究在将 ADX71149 加入护理标准时患者达到基线发作次数的主要终点未达到统计学意义，此后 Addex 股价走低